Fig 1.
Theoretical serotype coverage of PCV7 and PCV13 among (A) children < 2 years of age and (B) PCV7, PCV13 and PPV23 among adults ≥16 years of age with IPD in Germany. NVT1323: serotypes not included in PCV13 or PPV23. Bars correspond to left vertical axis, line corresponds to right vertical axis. Stacked bar for PPV23 serotypes should be interpreted without the bar for serotype 6A.
Fig 2.
Reported cases of IPD per 100,000 population.
All cases of invasive pneumococcal disease reported to the German National Reference Center for Streptococci between 1 July 2006 and 30 June 2018, per 100,000 population of Germany.
Fig 3.
Reported cases of IPD per 100,000 population of PCV13 serotypes with a residual prevalence of >1% in 2017/18.
Fig 4.
Coverage of current and future vaccine formulations among children <2 years (top) and among adults 60 years and older (bottom) with IPD in Germany.
PCV7 (purple), PCV13non7 (green), PCV15non13 (yellow) and PCV20non15 (orange). PPV23 serotypes not in PCV20 (blue), Serotype 6A (white). Exact values for individual serotypes are included in S2 Table. Data for 2003–2006 are composite numbers of the three epidemiological years, divided by three.
Fig 5.
Five-year projections for cases of invasive pneumococcal disease per 100,000 population, with and without a pneumococcal conjugate vaccine program for adults.
A linear trendline (y = 0.1903x+2.2067, R2 = 0.80) from reported cases of IPD occurring from 2013–2018 in adults over 60 was used to extrapolate reported case rates for the next five years (in dark blue). The data from S1 Table are shown here in light green to highlight the potential impact of direct protection on IPD in the older adult population in Germany.